Since the publication of this article, the authors have identified an error within the following sentence (page 1780):
Finally, Metzeler et al. 92 evaluated 46 elderly patients with AML treated with decitabine with or without the histone deacetylase inhibitor vorinostat, and found a significantly higher CR rate in patients with DNMT3A mutations (75%) versus wild-type DNMT3A (34%).
The correct sentence should read:
Finally, Metzeler et al. 92 evaluated 46 elderly patients with AML treated with decitabine with or without the proteasome inhibitor bortezomib, and found a significantly higher CR rate in patients with DNMT3A mutations (75%) versus wild-type DNMT3A (34%).
The authors would like to apologise for any inconvenience this may have caused.
